Antitumor effect of cisplatin incorporated into polylactic acid microcapsules

Artificial Organs

Volumn 23, Issue 2, 1999, Pages 161-168

  Araki, H ^a   Tani, T ^a   Kodama, M ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cisplatin; Drug delivery system; Microcapsule; Polylactic acid

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; ENCAPSULATION; MAMMALS; POLYESTERS; TARGETED DRUG DELIVERY; TOXICITY; TUMORS;

ANTITUMOR EFFECT; CIS-PLATIN; CISPLATIN; DISPERSING AGENT; DRUG-DELIVERY SYSTEMS; DRYING METHODS; MATRIX; MICROCAPSULES; SUSTAINED RELEASE; TUMOUR CELLS;

MICROSTRUCTURE;

CISPLATIN; POLYLACTIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; DIARRHEA; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG STORAGE; HUMAN; HUMAN CELL; INOCULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MICROCAPSULE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SURVIVAL TIME; SUSTAINED DRUG RELEASE; URINE INCONTINENCE; WASTING SYNDROME;

EID: 0033036405     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1999.06092.x     Document Type: Article

References (31)

1. 1. Youlten L. Lymphatics and lymph circulation. London: Pergamon Press 1960:470-510.
2. 2. Hagiwara A, Takahashi T, Ueda T, Lee R, Takeda M, Itoh T. Toxicity and pathological effects of a new dosage form of mitomycin C for carcinomatous peritonitis. Anticancer Res 1987;7:106-8.
3. 3. Hagiwara A, Takahashi T, Lee R, Ueda T, Takeda M, Itoh T. Enhanced chemotherapeutic efficacy on carcinomatous peritonitis using a new dosage form in animal experiments. Anticancer Res 1987;7:167-70.
4. 4. Hagiwara A, Takahashi T, Lee R, Ueda T, Takeda M, Itoh T. Selective delivery of high levels of mitomycin C to peritoneal carcinomatosis using a new dosage form. Anticancer Res 1986; 6:1161-4.
5. 5. Hagiwara A, Takahashi T, Lee R, Ueda T, Takeda M, Itoh T. Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Cancer 1987;59:245-51.
6. 6. Ptrestyko AW, D'Aoust CD, Issell BF, Crooke ST. Cisplatin (cis-diaminedichloroplatinum II). Cancer Treat Rev 1979;6: 17-39.
7. 7. Rossof AH, Slayton RE, Perlia CP. Preliminary clinical experience with cis-diaminedichloroplatinum II. Cancer 1972;30: 1451-6.
8. 8. Cutright DE, Ferez B, Beasley JD, Larson WJ, Posey WR. Degradation rates of polymers and copolylactic and poly glycolic acids. Oral Surg 1974;37:142-52.
9. 9. Cutright DE, Beasley JD, Perez B. Histologic comparison of polylactic and polyglycolic acid suture. Oral Surg 1971;32: 165-73.
10. 10. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull 1987;36:1095-1103.
11. 11. Ogawa Y, Okada H Yamamoto M, Shimamoto T. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or degradation of these polymers. Chem Pharm Bull 1988;36:2576-81.
12. 12. Toguchi H, Ogawa H, Okada H, Yamamoto M. Once-a-month injectable microcapsules of leuprolide acetate (in Japanese with English abstract). Yakugaku Zasshi 1991;111: 397-109.
13. 13. Ogawa Y. Microcapsule DDS using biodegradable polymers (in Japanese with English abstract). Drug Del Sys 1991;6: 165-70.
14. 14. Hagiwara A, Takahashi T, Kojima O, Yamaguchi T, Sasabe T, Lee M, Sasakura C, Shoubayashi S, Ikada Y, Hyon SH. Pharmacological effects of cisplatin microspheres on peritoneal carcinomatosis in rodents. Cancer 1992;71:844-50.
15. 15. Hagiwara A, Takahashi T, Sasabe T, Ito M, Lee M, Sakakura C, Shoubayashi S, Muranishi S, Tashima S. Toxicity of a new dosage format, cisplatin incorporated in lactic acid oligomer microspheres, in mice. Anticancer Drugs 1992;3:237-44.
16. 16. Sakakura C, Takahashi T, Hagiwara A, Itoh M, Sasabe T, Lee M, Shoubayashi S. Controlled release of cisplatin from lactic acid oligomer microspheres incorporating cisplatin: In vitro studies. J Controlled Release 1992;22:69-74.
17. 17. Ike O, Shimizu Y, Wada R, Okumura N, Hyon S-H, Watanabe S, Ikada Y. Experimental studies of a cisplatin delivery system for local chemotherapy of malignant diseases. Nippon Kokyuugeka Gakkai Zasshi 1990;6:87-91.
18. 18. Hagiwara A, Takahashi T, Yamaguchi T, Taniguchi H, Iwamoto A, Yoneyama C, Itoh M, Sasabe T, Lee M, Wada R, Hyon SH, Ikada Y. Intracavity microsphere incorporating cisplatinum for the treatment of malignant effusions-clinical trials (in Japanese with English abstract). Jpn J Cancer Chemother 1990;17:1575-8.
19. 19. Pera MF, Harder HC. Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 1977;23:1245-9.
20. 20. Brus I, Glass GBJ. Estimation of cytotoxic injury to gastric parietal cells by trypan blue exclusion test followed by hematoxylin-eosin counterstaining of fixed smears. Stain Tech 1973;48(3):127-32.
21. 21. Takahashi K, Ebihara K, Honda Y, Nisikawa K, Kita M, Oomura M, Shibasaki C. Antitumor activity of cis-dichlorodiamineplatinum (2) and its effect on cell cycle progression (in Japanese with English abstract). Gann To Kagakuryouhou 1981;9:349-631.
22. 22. Hasegawa Y, Morita M, Muto N. Antitumor activity of cisplatin on experimental animal system (in Japanese with English abstract). Gann To Kagakuryouhou 1980:7:621-30.
23. 23. Handel N, Silverstein MJ, Jensen JA, Collins A, Zierk K. Comparative experience with smooth and polyurethanc breast implants using the Kaplan-Meier method of survival analysis. Plast Reconstr Surg 1991;88(3):475-81.
24. 24. Araki H, Tani T, Yokota T, Numa K, Tsutamoto Y, Oka H, Ebira Y, Ameno H, Fujino M, Kobayashi C, Kodama M, Matsuo T. The development of PLGA microcapsules incorporated with cisplatin (in Japanese with English abstract). Jpn J Artif Organs 1995;24:226-8.
25. 25. Ebisui C, Tsujinaka T, Kido Y, Yano M, Ogawa A, Iijima S, Homma T, Kan K, Mori T. Appraisal of renovated infusion regimen for preventing CDDP induced nephrotoxicity (in Japanese with English abstract). J Jpn Surg Assoc 1994;55(4): 876-81.
26. 26. Boughattas NA, Li XM, Filipski J, Lemaigre G, Filipski E, Bouzouita K, Belhadj O, Levi F. Modulation of cisplatin chronotoxicity related to reduced glutathione in mice. Human Exp Toxicol 1996;15:563-72.
27. 27. Ueda H, Sugiyama K, Tashiro S, Yokota M. Mechanism of the protective effect of sodium malate on cisplatin-induced toxicity in mice. Biol Pharm Bull 1998;21(20):121-8.
28. 28. Ito K, Sakakibara T, Handa J, Irie Y, Tsubosaki M, Matsuda A. Safety test for Cisplatin (NK801) (in Japanese). Kiso To Rinshou 1981;15:5669-86.
29. 29. Oku M, Noda T, Kiyozuka Y, Ninomiya Y, Hino K, Okamura Y, Maruyama M, Ichijo M. Pharmacokinetic analysis of intraperitoneal cisplatin administration (in Japanese with English abstract). J Jpn Soc Cancer Ther 1988;23(30):657-64.
30. 30. Kumagai S, Sugiyama T, Nishida T, Ushijima K, Yakushiji M. Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres. Jpn J Cancer Res 1996;87:412-7.
31. 31. Tokuda K, Natsugoe S, Shimada M, Kumanohoso T, Yoshizawa H, Uemura Y, Hatate Y, Nakamura K, Yamada K, Nedachi M, Aiko T. Experimental study of cisplatin microspheres incorporated in polylactic acid and polyethylene glycol acid on peritoneal carcinomatosis in rats. Jpn J Cancer Chemother 1996;23(11):1516-8.